세계의 분산형 임상시험 시장(2023-2033년)

The global Decentralised Clinical Trials market is projected to grow at a CAGR of 7.6% by 2033

The Decentralised Clinical Trials Market Report 2023-2033: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.

The COVID-19 pandemic necessitated unprecedented adaptation on the part of life sciences organisations worldwide, for better or for worse, on a scale that has not been witnessed before in the contemporary industry. In response to the pandemic, biopharmaceutical companies and contract research organisations (CROs) have implemented decentralised or digital clinical trials (DCTs) as a means of minimising contact, enhancing the patient experience, and maintaining the progress of studies. The advantages of utilising virtual methods in the context of digital clinical trials are evident and have proven to be advantageous for life science entities. The clinical trial landscape has undergone a transformation with advancements in operational aspects such as patient engagement and site experience, cost reduction, and improved data integration. This shift has resulted in the acceptance of DCTs as a viable approach for conducting clinical studies.

Nevertheless, there are still obstacles to be overcome. The integration of conventional clinical trial obstacles with those arising from the shift towards digital solutions and decentralised designs characterises this novel clinical trial paradigm. The responsibility lies with biopharmaceutical companies and Contract Research Organizations (CROs) to comprehend and identify the challenges that arise during the implementation of a decentralised clinical trial. The achievement of academic success is contingent upon the assessment and integration of user-friendly remedies that can be expeditiously executed and simplified without imposing undue burden on healthcare professionals and recipients, all while upholding security and regulatory protocols.

What Questions Should You Ask before Buying a Market Research Report?

• How is the decentralised clinical trials market evolving?
  
• What is driving and restraining the decentralised clinical trials market?
  
• How will each decentralised clinical trials submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2033?
  
• How will the market shares for each decentralised clinical trials submarket develop from 2023 to 2033?
  
• What will be the main driver for the overall market from 2023 to 2033?
  
• Will leading decentralised clinical trials markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
  
• How will the market shares of the national markets change by 2033 and which geographical region will lead the market in 2033?
  
• Who are the leading players and what are their prospects over the forecast period?
  
• What are the decentralised clinical trials projects for these leading companies?
  
• How will the industry evolve during the period between 2023 and 2033? What are the implications of
  

decentralised clinical trials projects taking place now and over the next 10 years?

• Is there a greater need for product commercialisation to further scale the decentralised clinical trials market?
  
• Where is the decentralised clinical trials market heading and how can you ensure you are at the forefront of the market?
  
• What are the best investment options for new product and service lines?
  
• What are the key prospects for moving companies into a new growth path and C-suite?

You need to discover how this will impact the decentralised clinical trials market today, and over the next 10 years:

• Our 278-page report provides 120 tables and 158 charts/graphs exclusively to you.
  
• The report highlights key lucrative areas in the industry so you can target them - NOW.
  
• It contains in-depth analysis of global, regional and national sales and growth.
  
• It highlights for you the key successful trends, changes and revenue projections made by your competitors.

This report tells you TODAY how the decentralised clinical trials market will develop in the next 10 years, and in line with the variations in COVID-19 economic recession and bounce. This market is more critical now than at any point over the last 10 years.

Forecasts to 2033 and other analyses reveal commercial prospects

• In addition to revenue forecasting to 2033, our new study provides you with recent results, growth rates, and market shares.
  
• You will find original analyses, with business outlooks and developments.
  
• Discover qualitative analyses (including market dynamics, drivers, opportunities, and restraints), Porter's Five Forces Analysis, PEST Analysis and recent developments.

This report includes data analysis and invaluable insight into how COVID-19 will affect the industry and your company. Four COVID-19 recovery patterns and their impact, namely, "V", "L", "W" and "U" are discussed in this report.

Segments Covered in the Report

Indication

• Oncology
  
• Cardiovascular
  
• Immunology
  
• Respiratory
  
• Others

Study Design

• Interventional
  
• Observational
  
• Expanded Access

End-users

• Pharmaceutical and Biopharmaceutical Companies
  
• CROs
  
• Others

Component

• Mobile Healthcare
  
• Telemedicine
  
• Wearable Devices
  
• Web-based Technology
  
• Others

In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for five regional and 23 leading national markets:

North America

• U.S.
  
• Canada

Europe

• Germany
  
• UK
  
• France
  
• Italy
  
• Spain
  
• Rest of Europe

Asia Pacific

• Japan
  
• China
  
• India
  
• Australia
  
• South Korea
  
• Singapore
  
• Rest of Asia Pacific

Latin America

• Brazil
  
• Mexico
  
• Argentina
  
• Colombia
  
• Rest of Latin America

MEA

• GCC
  
• South Africa
  
• Rest of MEA

The report also includes profiles and for some of the leading companies in the Decentralised Clinical Trials Market, 2023 to 2033, with a focus on this segment of these companies' operations.

Leading companies and the potential for market growth

• CASTOR EDC
  
• Clinical ink
  
• CLOUDZBY, INC.
  
• Dassault Systemes (Medidata Solutions, Inc.)
  
• ERGOMED PLC
  
• FLORENCE HEALTHCARE INC.
  
• ICON PLC
  
• IQVIA Holdings, Inc.
  
• Labcorp Drug Development
  
• Medable, Inc.
  
• Medrio Inc.
  
• Oracle Corporation
  
• Parexel International Corporation
  
• PPD (Thermo Fisher Scientific Inc.)
  
• Syneos Health

Overall world revenue for Decentralised Clinical Trials Market, 2023 to 2033 in terms of value the market will surpass US$8,125.0 million in 2023, our work calculates. We predict strong revenue growth through to 2033. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

How will the Decentralised Clinical Trials Market, 2023 to 2033 report help you?

In summary, our 270+ page report provides you with the following knowledge:

• Revenue forecasts to 2033 for Decentralised Clinical Trials Market, 2023 to 2033 Market, with forecasts for indication, study design, end-users, and component, each forecast at a global and regional level - discover the industry's prospects, finding the most lucrative places for investments and revenues.
• Revenue forecasts to 2033 for five regional and 23 key national markets - See forecasts for the Decentralised Clinical Trials Market, 2023 to 2033 market in North America, Europe, Asia-Pacific, Latin America, and MEA. Also forecasted is the market in the US, Canada, Mexico, Brazil, Germany, France, UK, Italy, China, India, Japan, and Australia among other prominent economies.
• Prospects for established firms and those seeking to enter the market - including company profiles for 15 of the major companies involved in the Decentralised Clinical Trials Market, 2023 to 2033.

Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with invaluable business intelligence.

Information found nowhere else

With our new report, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Our study is for everybody needing commercial analyses for the Decentralised Clinical Trials Market, 2023 to 2033, market-leading companies. You will find data, trends and predictions.

Table of Contents

1 Report Overview

• 1.1 Objectives of the Study
• 1.2 Introduction to Decentralised Clinical Trials Market
• 1.3 What This Report Delivers
• 1.4 Why You Should Read This Report
• 1.5 Key Questions Answered by This Analytical Report Include:
• 1.6 Who is This Report For?
• 1.7 Methodology
  • 1.7.1 Market Definitions
  • 1.7.2 Market Evaluation & Forecasting Methodology
  • 1.7.3 Data Validation
    • 1.7.3.1 Primary Research
    • 1.7.3.2 Secondary Research
• 1.8 Frequently Asked Questions (FAQs)
• 1.9 Associated Reports
• 1.10 About

2 Executive Summary

3 Market Overview

• 3.1 Key Findings
• 3.2 Market Dynamics
  • 3.2.1 Market Driving Factors
    • 3.2.1.1 Advantages of Decentralised Trials Driving Market Growth
    • 3.2.1.2 Growing Adoption of Advanced Technologies is Boosting the Market Growth
    • 3.2.1.3 COVID-19 Pandemic is driving the Adoption of Decentralised Clinical Trials
    • 3.2.1.4 Rising Presence of CROs in Emerging Market is Boosting the Market Growth
  • 3.2.2 Market Restraining Factors
    • 3.2.2.1 Data Security Concerns Hinders the Market Growth
    • 3.2.2.2 Complex Supply Chain and Manufacturing Could limit the Entry of New Players
  • 3.2.3 Market Opportunities
    • 3.2.3.1 Evolution of Decentralised Trials Technologies is Projected to Boost the Market Growth
    • 3.2.3.2 Introduction of Advanced Cloud Platform
    • 3.2.3.3 Support from Government is Estimated to Propel Market Growth
    • 3.2.3.4 Mergers, Agreements, and Acquisitions by the Market Players is a Major Trend Witnessed in the Market
• 3.3 COVID-19 Impact Analysis
• 3.4 SWOT Analysis for Decentralised Clinical Trials Market
  • 3.4.1 Strengths
  • 3.4.2 Weaknesses
  • 3.4.3 Opportunities
  • 3.4.4 Threats
• 3.5 Porter's Five Forces Analysis
  • 3.5.1 Bargaining Power of Supplier
  • 3.5.2 Bargaining Power of Buyer
  • 3.5.3 Competitive Rivalry
  • 3.5.4 Threat of New Entrants
  • 3.5.5 Threat of Substitutes
• 3.6 PEST Analysis
  • 3.6.1 Political Factors Impacting Decentralised Clinical Trials Market
  • 3.6.2 Economic Factors Impacting Decentralised Clinical Trials Market
  • 3.6.3 Social Factors Impacting Decentralised Clinical Trials Market
  • 3.6.4 Technological Factors Impacting Decentralised Clinical Trials Market

4 Decentralised Clinical Trials Market Analysis by Indication

• 4.1 Key Findings
• 4.2 Indication Segment: Market Attractiveness Index
• 4.3 Decentralised Clinical Trials Market Size Estimation and Forecast by Indication
• 4.4 Oncology
  • 4.4.1 Market Forecast by Region, 2023-2033 (US$ Mn, AGR %)
  • 4.4.2 Market Share by Region, 2023 & 2033 (%)
• 4.5 Cardiovascular
  • 4.5.1 Market Forecast by Region, 2023-2033 (US$ Million, AGR %)
  • 4.5.2 Market Share by Region, 2023 & 2033 (%)
• 4.6 Immunology
  • 4.6.1 Market Forecast by Region, 2023-2033 (US$ Million, AGR %)
  • 4.6.2 Market Share by Region, 2023 & 2033 (%)
• 4.7 Respiratory
  • 4.7.1 Market Forecast by Region, 2023-2033 (US$ Mn, AGR %)
  • 4.7.2 Market Share by Region, 2023 & 2033 (%)
• 4.8 Others
  • 4.8.1 Market Forecast by Region, 2023-2033 (US$ Mn, AGR %)
  • 4.8.2 Market Share by Region, 2023 & 2033 (%)

5 Decentralised Clinical Trials Market Analysis by Study Design

• 5.1 Key Findings
• 5.2 Study Design Segment: Market Attractiveness Index
• 5.3 Decentralised Clinical Trials Market Size Estimation and Forecast by Study Design
• 5.4 Interventional
  • 5.4.1 Market Forecast by Region, 2023-2033 (US$ Mn, AGR %)
  • 5.4.2 Market Share by Region, 2023 & 2033 (%)
• 5.5 Observational
  • 5.5.1 Market Forecast by Region, 2023-2033 (US$ Mn, AGR %)
  • 5.5.2 Market Share by Region, 2023 & 2033 (%)
• 5.6 Expanded Access
  • 5.6.1 Market Forecast by Region, 2023-2033 (US$ Mn, AGR %)
  • 5.6.2 Market Share by Region, 2023 & 2033 (%)

6 Decentralised Clinical Trials Market Analysis by End-users

• 6.1 Key Findings
• 6.2 End-users Segment: Market Attractiveness Index
• 6.3 Decentralised Clinical Trials Market Size Estimation and Forecast by End-users
• 6.4 Pharmaceutical and Biopharmaceutical Companies
  • 6.4.1 Market Forecast by Region, 2023-2033 (US$ Mn, AGR %)
  • 6.4.2 Market Share by Region, 2023 & 2033 (%)
• 6.5 CROs
  • 6.5.1 Market Forecast by Region, 2023-2033 (US$ Mn, AGR %)
  • 6.5.2 Market Share by Region, 2023 & 2033 (%)
• 6.6 Others
  • 6.6.1 Market Forecast by Region, 2023-2033 (US$ Mn, AGR %)
  • 6.6.2 Market Share by Region, 2023 & 2033 (%)

7 Decentralised Clinical Trials Market Analysis by Component

• 7.1 Key Findings
• 7.2 Component Segment: Market Attractiveness Index
• 7.3 Decentralised Clinical Trials Market Size Estimation and Forecast by Component
• 7.4 Mobile Healthcare
  • 7.4.1 Market Forecast by Region, 2023-2033 (US$ Mn, AGR %)
  • 7.4.2 Market Share by Region, 2023 & 2033 (%)
• 7.5 Telemedicine
  • 7.5.1 Market Forecast by Region, 2023-2033 (US$ Mn, AGR %)
  • 7.5.2 Market Share by Region, 2023 & 2033 (%)
• 7.6 Wearable Devices
  • 7.6.1 Market Forecast by Region, 2023-2033 (US$ Mn, AGR %)
  • 7.6.2 Market Share by Region, 2023 & 2033 (%)
• 7.7 Web-based Technology
  • 7.7.1 Market Forecast by Region, 2023-2033 (US$ Mn, AGR %)
  • 7.7.2 Market Share by Region, 2023 & 2033 (%)
• 7.8 Others
  • 7.8.1 Market Forecast by Region, 2023-2033 (US$ Mn, AGR %)
  • 7.8.2 Market Share by Region, 2023 & 2033 (%)

8 Decentralised Clinical Trials Market Analysis by Region

• 8.1 Key Findings
• 8.2 Regional Market Size Estimation and Forecast

9 North America Decentralised Clinical Trials Market Analysis

• 9.1 Key Findings
• 9.2 North America Decentralised Clinical Trials Market Attractiveness Index
• 9.3 Market Size by Country, 2023, 2028 & 2033 (US$ Mn)
• 9.4 Market Size Estimation and Forecast by Country, 2023-2033 (US$ Mn)
• 9.5 Market Size Estimation and Forecast by Indication, 2023-2033 (US$ Mn)
• 9.6 Market Size Estimation and Forecast by Study Design, 2023-2033 (US$ Mn)
• 9.7 Market Size Estimation and Forecast by End-users, 2023-2033 (US$ Mn)
• 9.8 Market Size Estimation and Forecast by Component, 2023-2033 (US$ Mn)
• 9.9 U.S. Decentralised Clinical Trials Market Analysis
  • 9.9.1 Presence of Leading Players is a Major factor driving the U. S. Decentralised Clinical Trials Market
  • 9.9.2 U. S. Decentralised Clinical Trials Market Growth is Primarily Attributable to Growing R&D Expenditure and Outsourcing Activities
• 9.10 Canada Decentralised Clinical Trials Market Analysis
  • 9.10.1 Canada Market Anticipated to Witness the Fastest Growth in the North America Region
  • 9.10.2 Growing Canadian research collaborations determined to Provide Infrastructure for Cell-Based Therapy Research

10 Europe Decentralised Clinical Trials Market Analysis

• 10.1 Key Findings
• 10.2 Europe Decentralised Clinical Trials Market Attractiveness Index
• 10.3 Market Size by Country, 2023, 2028 & 2033 (US$ Mn)
• 10.4 Market Size Estimation and Forecast by Country, 2023-2033 (US$ Mn)
• 10.5 Market Size Estimation and Forecast by Indication, 2023-2033 (US$ Mn)
• 10.6 Market Size Estimation and Forecast by Study Design, 2023-2033 (US$ Mn)
• 10.7 Market Size Estimation and Forecast by End-users, 2023-2033 (US$ Mn)
• 10.8 Market Size Estimation and Forecast by Component, 2023-2033 (US$ Mn)
• 10.9 Germany Decentralised Clinical Trials Market Analysis
• 10.10 UK Decentralised Clinical Trials Market Analysis
• 10.11 France Decentralised Clinical Trials Market Analysis
• 10.12 Italy Decentralised Clinical Trials Market Analysis
• 10.13 Spain Decentralised Clinical Trials Market Analysis
• 10.14 Russia Decentralised Clinical Trials Market Analysis
• 10.15 Rest of Europe Decentralised Clinical Trials Market Analysis

11 Asia Pacific Decentralised Clinical Trials Market Analysis

• 11.1 Key Findings
• 11.2 Asia Pacific Decentralised Clinical Trials Market Attractiveness Index
• 11.3 Market Size by Country, 2023, 2028 & 2033 (US$ Mn)
• 11.4 Market Size Estimation and Forecast by Country, 2023-2033 (US$ Mn)
• 11.5 Market Size Estimation and Forecast by Indication, 2023-2033 (US$ Mn)
• 11.6 Market Size Estimation and Forecast by Study Design, 2023-2033 (US$ Mn)
• 11.7 Market Size Estimation and Forecast by End-users, 2023-2033 (US$ Mn)
• 11.8 Market Size Estimation and Forecast by Component, 2023-2033 (US$ Mn)
• 11.9 Japan Decentralised Clinical Trials Market Analysis
• 11.10 China Decentralised Clinical Trials Market Analysis
• 11.11 India Decentralised Clinical Trials Market Analysis
• 11.12 Australia Decentralised Clinical Trials Market Analysis
• 11.13 South Korea Decentralised Clinical Trials Market Analysis
• 11.14 Singapore Decentralised Clinical Trials Market Analysis
• 11.15 Rest of Asia Pacific Decentralised Clinical Trials Market Analysis

12 Latin America Decentralised Clinical Trials Market Analysis

• 12.1 Key Findings
• 12.2 Latin America Decentralised Clinical Trials Market Attractiveness Index
• 12.3 Market Size by Country, 2023, 2028 & 2033 (US$ Mn)
• 12.4 Market Size Estimation and Forecast by Country, 2023-2033 (US$ Mn)
• 12.5 Market Size Estimation and Forecast by Indication, 2023-2033 (US$ Mn)
• 12.6 Market Size Estimation and Forecast by Study Design, 2023-2033 (US$ Mn)
• 12.7 Market Size Estimation and Forecast by End-users, 2023-2033 (US$ Mn)
• 12.8 Market Size Estimation and Forecast by Component, 2023-2033 (US$ Mn)
• 12.9 Brazil Decentralised Clinical Trials Market Analysis
• 12.10 Mexico Decentralised Clinical Trials Market Analysis
• 12.11 Argentina Decentralised Clinical Trials Market Analysis
• 12.12 Colombia Decentralised Clinical Trials Market Analysis
• 12.13 Rest of Latin America Decentralised Clinical Trials Market Analysis

13 MEA Decentralised Clinical Trials Market Analysis

• 13.1 Key Findings
• 13.2 MEA Decentralised Clinical Trials Market Attractiveness Index
• 13.3 Market Size by Country, 2023, 2028 & 2033 (US$ Mn)
• 13.4 Market Size Estimation and Forecast by Country, 2023-2033 (US$ Mn)
• 13.5 Market Size Estimation and Forecast by Indication, 2023-2033 (US$ Mn)
• 13.6 Market Size Estimation and Forecast by Study Design, 2023-2033 (US$ Mn)
• 13.7 Market Size Estimation and Forecast by End-users, 2023-2033 (US$ Mn)
• 13.8 Market Size Estimation and Forecast by Component, 2023-2033 (US$ Mn)
• 13.9 GCC Decentralised Clinical Trials Market Analysis
• 13.10 South Africa Decentralised Clinical Trials Market Analysis
• 13.11 Rest of MEA Decentralised Clinical Trials Market Analysis

14 Company Profiles

• 14.1 IQVIA Holdings, Inc.
  • 14.1.1 Company Snapshot
  • 14.1.2 Company Overview
  • 14.1.3 Financial Analysis
    • 14.1.3.1 Net Revenue, 2015-2022
    • 14.1.3.2 Regional Market Shares, 2022
  • 14.1.4 Product Benchmarking
  • 14.1.5 Strategic Outlook
• 14.2 ICON PLC
  • 14.2.1 Company Snapshot
  • 14.2.2 Company Overview
  • 14.2.3 Financial Analysis
    • 14.2.3.1 Net Revenue, 2015-2022
    • 14.2.3.2 Regional Market Shares, 2022
  • 14.2.4 Product Benchmarking
  • 14.2.5 Strategic Outlook
• 14.3 Labcorp Drug Development
  • 14.3.1 Company Snapshot
  • 14.3.2 Company Overview
  • 14.3.3 Financial Analysis
    • 14.3.3.1 Net Revenue, 2015-2022
  • 14.3.4 Product Benchmarking
  • 14.3.5 Strategic Outlook
• 14.4 Dassault Systemes (Medidata Solutions, Inc.)
  • 14.4.1 Company Snapshot
  • 14.4.2 Company Overview
  • 14.4.3 Financial Analysis
    • 14.4.3.1 Net Revenue, 2015-2022
    • 14.4.3.2 Regional Market Shares, 2022
  • 14.4.4 Product Benchmarking
  • 14.4.5 Strategic Outlook
• 14.5 Oracle Corporation
  • 14.5.1 Company Snapshot
  • 14.5.2 Company Overview
  • 14.5.3 Financial Analysis
    • 14.5.3.1 Net Revenue, 2015-2022
    • 14.5.3.2 Regional Market Shares, 2022
  • 14.5.4 Product Benchmarking
  • 14.5.5 Strategic Outlook
• 14.6 Parexel International Corporation
  • 14.6.1 Company Snapshot
  • 14.6.2 Company Overview
  • 14.6.3 Product Benchmarking
  • 14.6.4 Strategic Outlook
• 14.7 Medrio Inc.
  • 14.7.1 Company Snapshot
  • 14.7.2 Company Overview
  • 14.7.3 Product Benchmarking
  • 14.7.4 Strategic Outlook
• 14.8 Medable, Inc.
  • 14.8.1 Company Snapshot
  • 14.8.2 Company Overview
  • 14.8.3 Product Benchmarking
  • 14.8.4 Strategic Outlook
• 14.9 Clinical ink
  • 14.9.1 Company Snapshot
  • 14.9.2 Company Overview
  • 14.9.3 Product Benchmarking
  • 14.9.4 Strategic Outlook
• 14.10 FLORENCE HEALTHCARE INC.
  • 14.10.1 Company Snapshot
  • 14.10.2 Company Overview
  • 14.10.3 Product Benchmarking
  • 14.10.4 Strategic Outlook
• 14.11 Syneos Health
  • 14.11.1 Company Snapshot
  • 14.11.2 Company Overview
  • 14.11.3 Financial Analysis
    • 14.11.3.1 Net Revenue, 2015-2022
    • 14.11.3.2 Regional Market Shares, 2022
  • 14.11.4 Product Benchmarking
  • 14.11.5 Strategic Outlook
• 14.12 PPD (Thermo Fisher Scientific Inc.)
  • 14.12.1 Company Snapshot
  • 14.12.2 Company Overview
  • 14.12.3 Financial Analysis
    • 14.12.3.1 Net Revenue, 2016-2020
  • 14.12.4 Product Benchmarking
  • 14.12.5 Strategic Outlook
• 14.13 CASTOR EDC
  • 14.13.1 Company Snapshot
  • 14.13.2 Company Overview
  • 14.13.3 Product Benchmarking
  • 14.13.4 Strategic Outlook
• 14.14 CLOUDZBY, INC.
  • 14.14.1 Company Snapshot
  • 14.14.2 Company Overview
  • 14.14.3 Product Benchmarking
  • 14.14.4 Strategic Outlook
• 14.15 ERGOMED PLC
  • 14.15.1 Company Snapshot
  • 14.15.2 Company Overview
  • 14.15.3 Financial Analysis
    • 14.15.3.1 Net Revenue, 2016-2020
    • 14.15.3.2 Regional Market Shares, 2022
  • 14.15.4 Product Benchmarking
  • 14.15.5 Strategic Outlook

15 Conclusion and Recommendations

• 15.1 Concluding Remarks from
• 15.2 Recommendations for Market Players